Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084721 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
A Phase 1 study of Colorectal Cancer and Diarrhea, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00084721: Completed Phase 1 study of Colorectal Cancer and Diarrhea, sponsored by Roswell Park Cancer Institute.
NCT00084721 is a Phase 1 study of Colorectal Cancer and Diarrhea that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 2 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084721, a Phase 1 study of Colorectal Cancer and Diarrhea, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving irinotecan with celecoxib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given with celecoxib in treating patients with unresectable or metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG irinotecan hydrochloride
- DRUG celecoxib
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-03 |
| Phase | Phase 1 |
What the finished NCT00084721 record still lists
NCT00084721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00084721 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00084721 about?
NCT00084721 is a clinical study titled "Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving irinotecan with celecoxib may kill more tumor cells...
What is the current status of trial NCT00084721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2005-03.
What conditions does trial NCT00084721 study?
This clinical trial studies the following conditions: Colorectal Cancer, Diarrhea.
What interventions are being tested in trial NCT00084721?
The interventions under investigation include: irinotecan hydrochloride (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00084721?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00084721 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00084721's enrollment target sits among peer trials
2 378th of 381 higher than 2 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia